Immuneering Overview
- Founded
-
2008
- Status
-
Public
- Employees
-
74
- Stock Symbol
-
IMRX
- Share Price
-
$6.37
- (As of Tuesday Closing)
Immuneering General Information
Description
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Stock Exchange
NAS
Primary Office
- 245 Main Street
- 2nd Floor
- Cambridge, MA 02142
- United States
+1 (617) 000-0000
Immuneering Timeline
Immuneering Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.37 | $6.63 | $3.74 - $24.75 | $175M | 26.4M | 55.8K |
Immuneering Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 254,767 | 276,684 | ||
| Revenue | 506 | 2,080 | 2,312 | 1,920 |
| EBITDA | (48,341) | (33,854) | (17,003) | (7,398) |
| Net Income | (48,052) | (33,536) | (17,040) | (7,709) |
| Total Assets | 133,692 | 166,705 | 38,423 | 14,099 |
| Total Debt | 4,851 | 5,365 | 621 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Immuneering Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Immuneering Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Immuneering Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debili
Drug Discovery
Cambridge, MA
74
As of 2022
00000
0000
0000-00-00
00000000
00000
000000
sectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim
0000 000000000
Brisbane, CA
00
As of 0000
000.00
00000000000
000.00
000000
ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolor
0000000000000
Berkeley, CA
000
As of 0000
00000
0000
0000-00-00
00000000
00000
Add Comparison
Immuneering Competitors (15)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Second Genome | Venture Capital-Backed | Brisbane, CA | 00 | 000.00 | 00000000000 | 000.00 |
| 0000000 0000000000 | Formerly VC-backed | Berkeley, CA | 000 | 00000 | 00000000 | 00000 |
| 00000000 000000 00 | Formerly VC-backed | Baltimore, MD | 000 | 00000 | 000000&0 | 00000 |
| 00000000 | Venture Capital-Backed | Houston, TX | 00 | 00.000 | 000000000 | 00.000 |
| 0000000000 | Formerly VC-backed | Menlo Park, CA | 000 | 00000 | 00000000 | 00000 |
Immuneering Patents
Immuneering Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3166636-A1 | Mek inhibitors and therapeutic uses thereof | Pending | 10-Jan-2020 | 0000000000 | |
| EP-4087840-A1 | Mek inhibitors and therapeutic uses thereof | Pending | 10-Jan-2020 | 0000000000 | |
| AU-2021206684-A1 | Mek inhibitors and therapeutic uses thereof | Pending | 10-Jan-2020 | 0000000000 | |
| US-11043305-B1 | Systems and methods for rapid gene set enrichment analysis | Active | 02-Feb-2018 | 000000000 | 00 |
| EP-3019865-A4 | Systems, methods, and environment for automated review of genomic data to identify downregulated and/or upregulated gene expression indicative of a disease or condition | Inactive | 12-Jul-2013 | G16B20/00 | 0 |
Immuneering Executive Team (9)
Immuneering Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Ann Berman | Immuneering | Board Member, Member of the Nominating and Corporate Governance Committee & Chair of the Audit Committee | 000 0000 |
| Bob Carpenter | Immuneering | Co-Founder & Chairman | 000 0000 |
| Diana Hausman MD | Immuneering | Board Member | 000 0000 |
| Joseph Kekst | Self | Board Member | 000 0000 |
| Laurie Keating JD | Immuneering | Board Member | 000 0000 |
Immuneering Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Immuneering Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|